CSF1R and acute myeloid leukemia: CSF1R inhibition alone may not be sufficient to overcome resistance mechanisms in vivo [92,93], but it may represent a general approach to target the microenvironment of AML cells and may be promising when used in combination with inhibitors of the immune checkpoints, angiogenesis, or with the adoptive T-cell transfer, which are undergoing clinical investigations [94].